Mental health in UK Biobank – development, implementation and results from an online questionnaire completed by 157 366 participants: a reanalysis*


Background
UK Biobank is a well-characterised cohort of over 500 000 participants including genetics, environmental data and imaging. An online mental health questionnaire was designed for UK Biobank participants to expand its potential.

Aims
Describe the development, implementation and results of this questionnaire.

Method
An expert working group designed the questionnaire, using established measures where possible, and consulting a patient group. Operational criteria were agreed for defining likely disorder and risk states, including lifetime depression, mania/ hypomania, generalised anxiety disorder, unusual experiences and self-harm, and current post-traumatic stress and hazardous/ harmful alcohol use.

Results
A total of 157 366 completed online questionnaires were available by August 2017. Participants were aged 45–82 (63% were ≥65 years) and 57% women. Comparison of self-reported diagnosed mental disorder with a contemporary study shows a similar prevalence, despite respondents being of higher average socioeconomic status. Lifetime depression was a common finding, with 24% (37 434) of participants meeting criteria and current hazardous/harmful alcohol use criteria were met by 21% (32 602), whereas other criteria were met by less than 8% of the participants. There was extensive comorbidity among the syndromes. Mental disorders were associated with a high neuroticism score, adverse life events and long-term illness; addiction and bipolar affective disorder in particular were associated with measures of deprivation.

Conclusions
The UK Biobank questionnaire represents a very large mental health survey in itself, and the results presented here show high face validity, although caution is needed because of selection bias. Built into UK Biobank, these data intersect with other health data to offer unparalleled potential for crosscutting biomedical research involving mental health.

Declaration of interest
G.B. reports grants from the National Institute for Health Research during the conduct of the study; support from Illumina Ltd and the European Commission outside the submitted work. B.C. reports grants from the Scottish Executive Chief Scientist Office during the conduct of the study. C.S. reports grants from the Medical Research Council and Wellcome Trust, during the conduct of the study; and is the former Chief Scientist for UK Biobank. M.H. reports grants for IMI RADAR-CNS and personal fees as an expert witness outside the submitted work. N.A. is Chief Scientist for UK Biobank. Other authors have nothing to declare.

Keywords
Mental health; UK Biobank; cohort study; depressive disorders; alcohol disorders.

Copyright and usage
© The Author(s) 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

UK Biobank
UK Biobank is a very large, population-based cohort study established to identify the determinants of common life-threatening and disabling conditions. Most of these conditions, such as heart disease, stroke and mental disorders, are multifactorial, involving multiple genes of small effect, and complex relationships with environmental exposures. This means large samples are required to study associations between these exposures and disease, and to identify targets for treatment and prevention. The utility of traditional epidemiological study designs are often limited by their focus on single disorders or exposures and relatively modest sample sizes. UK Biobank is an open-access resource providing detailed characterisation of over half a million people aged 40–69 years at recruitment, with proposed long-term follow-up. Recruitment was completed in 2010, along with consent for future contact and linkage to routinely collected health-related data, such as those produced by the National Health Service (NHS). Baseline measures were extensive, from family history to sensory acuity (a searchable breakdown is available at www.ukbiobank.ac.uk), and the resource continues to grow. In 2017 genotyping of the whole cohort was complete, a range of blood biomarkers were released in 2019, and multimodal imaging is underway for 100 000 participants. Locality environmental factors, such as air pollution, are also available. The design of UK Biobank offers the opportunity to examine a wide range of

risk factors and outcomes in a sample that has the size to provide the power to detect small effects, making UK Biobank a highly efficient resource for observational epidemiology.

The impact of mental disorders on disability and quality of life is considerable, accounting for the equivalent of over 1.2 million person-years lost to disability from mental and substance-use disorders in England alone in 2013. The detrimental impact of mental disorders both on physical disease onset and outcomes is particularly notable for this project. The UK Biobank baseline data collection of mental health, consisted of several questions about mood and a neuroticism scale, expanded for the last 172 729 recruited participants with questions to allow provisional categorisation of mood disorder, however, there was considerable scope for further characterisation of mental disorders among participants. The availability of mental health phenotypes in conjunction with the wealth of other data in the UK Biobank offers considerable opportunities to study aetiological and prognostic factors, particularly the interplay between factors that have usually been in separate research domains.

Outcome ascertainment

Characterising mental disorders in a cohort such as UK Biobank poses challenges. First, most mental disorders manifest before age 30 years and have fluctuating courses, so a 'snapshot' of disorder status at one point in time, as identified by most screening tools, is likely to be less useful than a 'lifetime' history – although 'lifetime' instruments suffer more from measurement error such as recall bias. Second, traditional diagnostic approaches to mental disorders, relying upon clinician assessment at interview, would be prohibitively expensive in a cohort of this size. Third, using self-report of diagnosis or data from record linkages relies upon recognition of illness and reflects healthcare usage patterns, whereas many people with mental disorders never seek or receive treatment. In response to these challenges, we developed a dual approach: secondary record linkage for the identification of more severe illnesses such as schizophrenia and self-report of symptoms of common mental disorder, which might not have come to clinical attention. As part of our mental health phenotyping programme we therefore developed an online mental health questionnaire (MHQ) for participants to complete regarding lifetime symptoms of mental disorders. The MHQ aimed to exploit the efficiency of 'e-surveys' and provide the detail needed to identify mental health disorders without the need for a clinical assessment.

Aims

The present paper aims to describe the development, implementation and results of the MHQ. We provide descriptive data on the numbers of UK Biobank participants meeting diagnostic criteria for specific disorders and on the frequency of exposure to risk factors. We also evaluate the likely representativeness of respondents by comparing respondent sociodemographic characteristics to that of the UK population using census data and comparing self-reported mental disorder diagnosis with the Health Survey for England (HSE) data. This will assist researchers considering or undertaking epidemiological research to evaluate the potential strengths and weaknesses of using UK Biobank data to look at mental health.

Method

Questionnaire development

A mental health research reference group formed of approximately 50 individuals (see supplementary Appendix 1 available at https://doi.org/10.1192/bj.2019.100) participated in discussions about a strategy for mental health phenotyping in UK Biobank, including a workshop in January 2015. From this, a smaller steering group was established and led the development of the MHQ. The group recommended that the MHQ should concentrate on depression, as it was likely to represent the greatest burden in the cohort, with some questions about other common disorders, including anxiety, alcohol misuse and addiction, plus risk factors for mental disorders not captured at participants’ baseline assessment.

The intention was to create a composite questionnaire out of previously existing and validated measures, taking into account participant acceptability (time, ease of use and ensuring questions were unlikely to offend), scope for collaborations with international studies (for example the Psychiatric Genomics Consortium) through making results comparable, and the need to balance depth and breadth of phenotyping. The base of the questionnaire was the measurement of lifetime depressive disorder using the Composite International Diagnostic Interview Short Form (CIDI-SF), modified to provide lifetime history, as used to identify cases and controls for some existing studies in the Psychiatric Genomics Consortium. The CIDI-SF uses a branching structure with screening questions and skip rules to limit detailed questions to the relevant areas for each participant. Other measures were then added to this, as summarised in supplementary Table SM1. Where the group were unable to find existing measures that fulfilled these criteria, questions were written or adapted, as indicated in supplementary Table SM1. These sections have not been externally validated, but the questions along with the full questionnaire can be seen on the UK Biobank website (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=22), for researchers to evaluate.

Testing and ethical approval

The use of branching questions in the MHQ means that those with established and multiple mental disorders have a longer, more detailed, questionnaire. To improve acceptability in this group, we worked with a patient advisory group at the National Institute of Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust in designing the questionnaire and invitation. We then piloted the questionnaire for functionality (for example ease of completion) among an online cohort of 14 836 volunteers aged over 50 and living in the UK, who completed the questionnaire as part of signing up to take part in the Platform for Research Online to investigate Genetics and Cognition in Ageing (PROTECT). Of those who started the questionnaire 98.8% completed it, taking a median time of 15 min. Some PROTECT participants commented that they wanted the opportunity to explain why they felt they had experienced symptoms of depression. In response to this, we added a question to the depression section on loss or bereavement, and a free-text box – neither were designed to change diagnostic algorithms, but may add to future analyses.

The questionnaire was approved as a substantial amendment to UK Biobank approval from the North West - Haydock Research Ethics Committee, 11/NW/0382. Participation in the UK Biobank is voluntary, and participants are free to withdraw at any time. Informed written consent was obtained by participants at baseline. Online questionnaires such as the MHQ are voluntary.

Administration to UK Biobank participants

We incorporated the final MHQ into the UK Biobank web-questionnaire platform and presented it to participants as an online questionnaire entitled ‘thoughts and feelings’. To participants who had agreed to email contact (339 092/503 328 participants, 67%) we sent a hyperlink to their personalised questionnaire. The
invited to complete the MHQ were not included in the analysis. The MHQ will continue to be available on the participant area of the UK Biobank website, and since 2017 the annual postal newsletter contains an invitation to log on to the participant area and complete questionnaires, which will reach those for whom no email contact was possible. Data from the MHQ will therefore continue to accrue. The current numbers and aggregate data can be accessed from the public data showcase (http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=136). More detail on the rollout and associated communications can be found on the UK Biobank website (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=22).

Defining outcomes from the MHQ

Some suggested case definitions for the evaluation of the responses on the MHQ are detailed in supplementary Appendix 2. They arose either from the instruments used in the MHQ or by consensus criteria agreed by the working committee who wrote the MHQ. Diagnostic criteria were evaluated for depression (major depressive disorder), hypomania or mania, generalised anxiety disorder (GAD), hazardous/harmful alcohol use (alcohol use disorder) and post-traumatic stress disorder (PTSD). Addiction to substances and/or behaviour was defined based on self-report alone. Unusual experiences (describing potential symptoms of psychosis) and self-harm were also defined as phenomena that are important for phenotyping, but are not specific to any disorder. We combined outcomes to divide the cohort into five mood disorder groups, as shown in supplementary Fig. MD1.

Fulfilling the diagnostic criteria based on a self-report questionnaire does not allow us to rule out other psychiatric disorders, psychological or situational factors that might better explain the symptoms, which may have been elicited had there been a clinical evaluation. Therefore, we would regard any case classification arising from the MHQ as ‘likely’, rather than a confirmed psychiatric disorder. The issue becomes particularly problematic for disorders that are less common in the population, such as bipolar affective disorder, where literature shows that using questionnaires to screen the population may overestimate prevalence. Therefore, although we report the presence of hypomania/mania symptoms for the whole population, we only make the likely diagnosis of bipolar affective disorder in people with a history of depression, a subpopulation where the prevalence of bipolar affective disorder is higher, and therefore screening questionnaires have better positive predictive values.

Analysis and data sharing

Data were supplied by UK Biobank on 8 August 2017 under application number 16577. This data is open-access subject to the usual conditions. This study is part of a larger project, the UK Biobank, which continues to accrue. The current numbers and aggregate data can be accessed from the public data showcase (http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=136). More detail on the rollout and associated communications can be found on the UK Biobank website (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=22).

Comparison data

In order to describe the differences in the sample of participants in UK Biobank to the general population of the UK, Fry et al. compare UK Biobank data with census data, which we have replicated and extended. For health-related data, we have used the Health Survey for England (HSE), which is a face-to-face household survey carried out every year, that in 2014 involved around 8000 adult participants designed to be representative of the England adult population (with weighting in cases where sampling could not achieve this). Some topics are ‘core’ and are surveyed every year, whereas others are ‘supplementary’. Mental health appeared in the 2014 survey as a supplementary topic.

Results

The setting, recruitment and methods of selection of participants in UK Biobank have been published elsewhere. For the MHQ study, 339,092 participants were sent an email invitation, and 157,366 (46% of those emailed) fully completed the questionnaire by July 2017 (available in August 2017) – which means that the MHQ had 31% coverage of the UK Biobank cohort. The coverage continues to grow as the questionnaire is still open for participants. Figure 1 shows the flow chart of UK Biobank participants who completed the MHQ. The median time for completion was 14 min, and 82% of respondents completed the questionnaire in under 25 min.

Supplementary Table SM2 shows participant characteristics for all UK Biobank participants and those who completed the MHQ compared with population-level data for UK residents in the same age range. The MHQ participants were aged 45–82 years, with 53% aged 65 or over, and 57% were female. They were different from the whole UK Biobank cohort and the general population by being better educated (for example 45% hold a degree v. 32% of all UK Biobank participants v. 23% in the census), of higher socio-economic status according to job type, and healthier (28% report long-standing illness or disability v. 32% all UK Biobank participants v. 37% census), with lower rates of current smoking.

Table 1 shows that 34% of respondents reported they had received at least one psychiatric diagnosis from a professional at some time, and 12% had received two or more. The most commonly reported diagnosis was depression, followed by ‘anxiety or nerves’. Data are compared with the population prevalence estimates from HSE for this age group. The comparison shows that the pattern and prevalence of diagnosis are similar; for example, a depression diagnosis was self-reported by 21% of individuals in both samples, eating disorder by around 1% and bipolar-related disorders by around 0.5%. The definition in the MHQ differed from that in the HSE for anxiety (the MHQ definition was broader) and addiction (MHQ did not require professional diagnosis), and the higher overall prevalence in the UK Biobank MHQ compared with the HSE (34.3% v. 28.0%) may be a result of those wider definitions.

Table 2 shows that 45% of participants met criteria for one or more operationally defined syndromes. Of the lifetime disorders, depression was most common (24% respondents participants), the purpose of reproducing these analyses or developing further analyses.
then GAD (7%) and hypomania/mania (2%); current hazardous/harmful alcohol use was met by 21% and current PTSD by 6%. Lifetime unusual experiences were reported by 5% of respondents and self-harm by 4%. Supplementary Table SM3 shows that women and men were approximately equally likely to have a history of one or more of the defined syndromes (women 44% v. men 46%), but differed as to which criteria were met: women were more likely to have a history of depression or anxiety disorder, whereas men were more likely to meet criteria for a current hazardous/harmful alcohol use (women 14% v. men 30%). Table 2 also shows the substantial comorbidity of defined syndromes. Notably, around three-quarters of participants who met criteria for lifetime anxiety disorder also met criteria for lifetime depression. Also, although individuals meeting criteria for PTSD had more than a twofold risk of all of the lifetime syndromes compared with average, those identified with hazardous/harmful alcohol use had little extra risk of lifetime syndromes.

In Table 3, people meeting criteria for the lifetime occurrence of at least one of depression, bipolar disorder, GAD, unusual experiences or self-reported addiction are seen to be more likely than those without to come from a younger age group, report adverse life events and have met criteria for loneliness or social isolation. They are more likely to have smoked cigarettes and/or used cannabis, and to have had a ‘longstanding illness’ at baseline (although the presence of a mental disorder may have been the illness to which the participants refer in some cases), but all groups were equally likely to be achieving recommended levels of physical activity. Markers of deprivation (area-level deprivation and rented housing) are raised in groups with a history of mental disorders, especially bipolar affective disorder and additions.

The supplementary material includes a section on mood disorder, showing the results of analyses of MHQ participants by likely disorder categories (supplementary Fig. MD1). Supplementary Table MD1 shows the features of these groups. The characteristics of people who meet diagnostic criteria for depression appear to be shared by those with subthreshold depressive symptoms. Supplementary Table MD2 shows comorbidity, and demonstrates a gradient effect in the presence of a non-depression syndrome rising from 23% in no depression (mainly hazardous/harmful alcohol use) to 50% in recurrent depression. Supplementary Table MD3 shows that people with a history of depression or bipolar affective disorder tend to have worse scores for current mental health.

### Discussion

**Main findings relating to data-collection methods**

This paper has described the development, implementation and principal descriptive findings from the UK Biobank MHQ. The implementation of this questionnaire demonstrates that a web-based questionnaire is an acceptable means of collecting mental health information at low cost and large scale. Although the data-collection methods might force more limited data acquisition than conventional interview methods, with associated uncertainties in true diagnostic categorisation, we suggest that the survey achieved an acceptable trade-off between depth of phenotypic information and scale of sample size. This means that the UK Biobank MHQ sample can usefully fill a gap between clinical samples with detailed mental health disorder information but poor generalisability (for example, Clinical Records Interactive Search(26)) and larger...
cohorts with superficial identification of mental disorder (such as the baseline UK Biobank cohort or 23andMe\textsuperscript{27}).

The MHQ achieved a participation rate of 31\% of the original UK Biobank participants and 46\% of those emailed. This response rate is largely owing to the attention paid to ensure the acceptability of Biobank participants and 46\% of those emailed. This response rate is 20.8% (19.4–22.2).

Main findings from the questionnaire

Those who completed the MHQ appear to be better educated and have higher socioeconomic status (job title, household income, home ownership and area-level deprivation) than those recruited into UK Biobank overall, and the UK population. Despite this, we found that rates of self-report diagnoses were similar to population

Table 1

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>UK Biobank MHQ responses, age 45–82 years (n = 157 366)</th>
<th>HSE, age 45–84 years (n = 3272)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>% in sample</td>
</tr>
<tr>
<td>All psychiatric disorders</td>
<td>723</td>
<td>0.5</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>157</td>
<td>0.1</td>
</tr>
<tr>
<td>Any other type of psychosis or psychotic illness</td>
<td>604</td>
<td>0.4</td>
</tr>
<tr>
<td>Depression</td>
<td>33 424</td>
<td>21.2</td>
</tr>
<tr>
<td>Mania, hypomania, bipolar or manic-depression</td>
<td>837</td>
<td>0.5</td>
</tr>
<tr>
<td>Anxiety, nerves or generalised anxiety disorder\textsuperscript{b}</td>
<td>22 036</td>
<td>14.0</td>
</tr>
<tr>
<td>Panic attacks</td>
<td>87 004</td>
<td>5.5</td>
</tr>
<tr>
<td>Agoraphobia</td>
<td>599</td>
<td>0.4</td>
</tr>
<tr>
<td>Social anxiety or social phobia</td>
<td>1962</td>
<td>1.2</td>
</tr>
<tr>
<td>Any other phobia (for example disabling fear of heights or spiders)</td>
<td>2153</td>
<td>1.4</td>
</tr>
<tr>
<td>Obsessive–compulsive disorder</td>
<td>982</td>
<td>0.6</td>
</tr>
<tr>
<td>A personality disorder</td>
<td>385</td>
<td>0.2</td>
</tr>
<tr>
<td>All eating disorders</td>
<td>1851</td>
<td>1.2</td>
</tr>
<tr>
<td>Anorexia nervosa</td>
<td>891</td>
<td>0.6</td>
</tr>
<tr>
<td>Bulimia nervosa</td>
<td>503</td>
<td>0.3</td>
</tr>
<tr>
<td>Psychological overeating or binge-eating</td>
<td>707</td>
<td>0.4</td>
</tr>
<tr>
<td>Autism, Asperger's or autistic spectrum disorder</td>
<td>223</td>
<td>0.1</td>
</tr>
<tr>
<td>Attention-deficit or attention-deficit hyperactivity disorder</td>
<td>133</td>
<td>0.1</td>
</tr>
<tr>
<td>Any addiction or dependence</td>
<td>9386</td>
<td>6.0</td>
</tr>
<tr>
<td>Alcohol or drug addiction\textsuperscript{c}</td>
<td>5002</td>
<td>3.2</td>
</tr>
<tr>
<td>Physical alcohol dependence</td>
<td>946</td>
<td>0.6</td>
</tr>
</tbody>
</table>

MHQ, mental health questionnaire; NR, not reported.

The MHQ achieved a participation rate of 31\% of the original UK Biobank participants and 46\% of those emailed. This response rate is substantially higher than previous UK Biobank questionnaires, largely owing to the attention paid to ensure the acceptability of the invitation and questionnaire and the efficient use of reminders.

Table 2

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Overall Prevalence, n (%)</th>
<th>Comorbidity, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 157 366)</td>
<td>Depression\textsuperscript{b}</td>
</tr>
<tr>
<td>Total</td>
<td>70 892 (45)</td>
<td>37 434 (24)</td>
</tr>
<tr>
<td>Lifetime history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression\textsuperscript{b}</td>
<td>37 434 (24)</td>
<td>–</td>
</tr>
<tr>
<td>Hypomania/mania\textsuperscript{a}</td>
<td>2396 (2)</td>
<td>1550 (65)</td>
</tr>
<tr>
<td>Anxiety disorder\textsuperscript{d}</td>
<td>11 111 (7)</td>
<td>8444 (76)</td>
</tr>
<tr>
<td>Unusual experiences\textsuperscript{e}</td>
<td>7803 (5)</td>
<td>3649 (47)</td>
</tr>
<tr>
<td>Self-harm\textsuperscript{f}</td>
<td>6872 (4)</td>
<td>4240 (62)</td>
</tr>
<tr>
<td>Current</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hazardous/harmful alcohol use\textsuperscript{e}</td>
<td>32 602 (21)</td>
<td>8156 (25)</td>
</tr>
<tr>
<td>PTSD\textsuperscript{h}</td>
<td>10 064 (6)</td>
<td>6373 (63)</td>
</tr>
</tbody>
</table>

PTSD, post-traumatic stress disorder.

a. Percentages refer to the proportion of participants with the row syndrome who also have column syndrome. See footnotes b–h, and supplementary Appendix 2 for ‘case’ definitions.

b. Criteria met for major depressive disorder on Composite International Diagnostic Interview Short Form (CID-I-SF) lifetime.

c. Criteria met for hypomania/mania lasting for at least 1 week.

d. Criteria met for generalised anxiety disorder on CID-I-SF lifetime.

e. Reported potential hallucination or delusion at any point in their life.

f. Reported self-harm at some point in their life, asked to report self-harm ‘whether or not you meant to end your life’.

h. Score above cut-off for alcohol use disorder (PAS or Alcohol Use Disorder Identification Tool during the past year.

i. Criteria met for post-traumatic stress disorder (PTSD) on PTSD Checklist - Short version (PCL-S) in the past month.
estimates from the HSE. The patterns of association between disorders and demographics were also broadly as predicted by previous research, which adds to the face validity of the questionnaire. For example, depression and anxiety were more common in women, whereas addiction and alcohol misuse were more common in men, and all disorders were less common in respondents older than 65 years. The decrease in prevalence of lifetime disorder with increasing age has been previously noted in cross-sectional studies, although the causes and implications are not clearly understood. The high level of hazardous/harmful alcohol (using the Alcohol Use Disorder Identification Tool) is consistent with the established literature, supporting the use of the data to study the relationships between exposures and outcomes. Previous work on health surveys with selection bias because of non-participation, including UK Biobank, have indicated that they can be used to give estimates of association, although biased results may occur in some cases. For example, the relative under-participation of unskilled workers in the MHQ (around one-fifth of the proportion in the population) could mask an association with a variable that was related to unskilled work.

### Strengths and limitations

We developed a questionnaire through a consensus approach with clear aims of capturing enough data to characterise participants as having a lifetime history of depression and other phenotypes. Validated instruments were used where possible. The consortium working on the questionnaire included mental health researchers and members of the UK Biobank team working in collaboration to develop the optimum approach. The derived variables of likely categorical diagnoses will be added to the UK Biobank resource, facilitating those less familiar with mental health to use the results.
efficiently. The UK Biobank data, including that from the MHQ, is available to researchers and we have made the code used to derive the results in this paper freely available, allowing other researchers both to query our findings and build upon them for their own work.

The ‘healthy volunteer’ effect may limit applications of the data. The questionnaire was also heavily reliant on participant report, which may be affected by the stigma of reporting psychiatric symptoms, and tends to underestimate lifetime prevalence through forgetting or re-evaluating distant events. This caveat on ‘lifetime’ disorder is another reason this data is more suitable for association studies than prevalence estimates. Researchers considering the use of UK Biobank data will need to assess the likely impact of selection bias and recall bias on a case-by-case basis, as this will affect whether UK Biobank is suitable and the choice of mental health data within UK Biobank.

As a result of restrictions of time and space, the questionnaire was limited in the topics it could cover. The focus of the questionnaire was on categorical diagnoses rather than dimensional traits, which will tend to confirm conventional ICD/DSM nosology of psychiatric disorder and may not suit some research. In particular, tools were chosen that are based on DSM-IV disorders, which reflects current practise (for example National Institute for Health and Care Excellence guidelines on depression and anxiety use DSM-IV definitions). Of the disorders with operational classification, all would generalise to DSM-5, except PTSD, and the concepts are valid for ICD-10 disorders, although the threshold of disorder may be different, for example depression is diagnosed with fewer symptoms in DSM than ICD. Developments in UK Biobank such as primary care linkage and proposed future questionnaires (such as quality of life, activities of daily living) will continue to enrich the picture of mental health in the cohort going forward.

Implications

In conclusion, UK Biobank offers a unique opportunity to research common disorders in a well-characterised longitudinal cohort of UK adults. A detailed MHQ has now been completed by 157 366 participants, including self-report, operationally defined lifetime disorder status and detailed phenotype information on mood disorder. The proportion of participants with mental disorders and the patterns of participants experiencing symptoms and disorders was expected despite a ‘healthy volunteer’ selection bias. Further work on mental health phenotyping for UK Biobank includes validation of Hospital Episode Statistics for mental health diagnoses, incorporation of general practice records, triangulation of health record and questionnaire data, and investigation of further putative phenotypes. Existing projects utilising UK Biobank mental health data can be seen in a searchable database of approved research (http://www.ukbiobank.ac.uk/approved-research/).

This study also demonstrates the substantial burden of mental health disorders, including potentially dangerous patterns of alcohol consumption. Given the known impact of mental health on physical health, mental health data and its associations should interest researchers from every biomedical speciality. This study suggests that UK Biobank could be a powerful tool for such studies, and as it is open to all bona fide health researchers for work in the public good, we hope this study will inspire both existing and new users of UK Biobank.

Funding

This paper represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. High performance computing facilities were funded with capital equipment grants from the Gatsby Charity (TR130505) and Maudsley Charity (TR120996). Individual authors acknowledge the following additional funding: M.A. is supported by a Wellcome Trust Strategic Award (Reference 10436/Z/14/Z). B.C. is funded by the Scottish Executive Chief Scientist Office (DTI/74/03) and by The Dr Mortimer and Theresa Sackler Foundation. E.F. is supported by the European Research Council (ERC) under the European Union’s Seventh Framework Programme (FP7/2007-2013/ ERC grant agreement no. 304176). L.M.H. is supported by an NIHR Research Professorship (RP-3-12-123). A.J. is funded by the NIHR Biomedical Research Centre (No: BRC-2012-251) and Medical Research Council (MRC) (MC-FCP-10004). W.L. is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Maudsley, Institute of Psychiatry, Psychology and Neuroscience, King’s College London; and South London and Maudsley NHS Foundation Trust, NIHR Biomedical Research Centre, UK.

Acknowledgements

We thank the staff and participants of UK Biobank, the PROTECT study and the South London and Maudsley NHS Foundation Trust Service Users Group for their participation. High performance computing facilities were funded with capital equipment grants from the Gatsby and St Thomas’s Charity (TR130505) and Maudsley Charity (98B).

Data availability

Available from UK Biobank subject to standard procedures (www.ukbiobank.ac.uk). For replication available from Mendeley Data (http://doi.org/10.17632/kv677c2th4.3).

Author contributions

All authors contributed to the IMCE criteria for authorship. K.A.S.D., G.B., E.F., L.M.H., A.J., R.M., A.M., D.J.S., C.S., S.Z. and M.H. designed the study. N.A. and J.H. co-ordinated the delivery of the questionnaire. J.H. and K.A.S.D. coded the questionnaire and annotations. A.M. is supported by a Wellcome Trust Strategic Award (Reference 10436/Z/14/Z). D.J.S. is supported by a Wellcome Trust Strategic Award (Reference 10436/Z/14/Z) and by the European Research Council (ERC) under the European Union’s Seventh Framework Programme (FP7/2007-2013/ ERC grant agreement no: 324176). L.M.H. is supported by an NIHR Research Professorship (RP-3-12-123). A.J. is funded by the NIHR Biomedical Research Centre (No: BRC-2012-251) and Medical Research Council (MRC) (MC-FCP-10004). W.L. is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Maudsley, Institute of Psychiatry, Psychology and Neuroscience, King’s College London; and South London and Maudsley NHS Foundation Trust, NIHR Biomedical Research Centre, UK.

Correspondence: Matthew Hotopf. Email: matthew.hotopf@kcl.ac.uk.

First received 28 Jun 2019, final revision 19 Nov 2019, accepted 17 Dec 2019.

Downloaded from https://www.cambridge.org/core, subject to the Cambridge Core terms of use.
of the questionnaire. G.B. and J.R.I.C. curated data. G.B. and J.R.I.C. contributed to analysis. K.A.S.D., R.P., D.J.S. and M.H. wrote the paper. All authors critically edited the paper. All authors agreed to submission.

Supplementary material
Supplementary material is available online at https://doi.org/10.1102/bjp.2019.100.

References